Multicenter, Single-Arm Phase II Study of Nab-Paclitaxel/Carboplatin in Untreated PS2 Patients with Advanced NSCLC: TORG1426

被引：0

作者：

Naoki, K. ^{[1
]}

Ichikawa, Y. ^{[2
]}

Bessho, A. ^{[3
]}

Hosokawa, S. ^{[3
]}

Shimokawa, T. ^{[4
]}

Yomota, M. ^{[5
]}

Hosomi, Y. ^{[5
]}

Otani, S. ^{[1
]}

Nakahara, Y. ^{[1
]}

Iwasawa, S. ^{[6
]}

Tokito, T. ^{[7
]}

Seki, N. ^{[2
]}

Okamoto, H. ^{[8
]}

机构：

[1] Kitasato Univ, Sch Med, Resp Med, Sagamihara, Kanagawa, Japan

[2] Teikyo Univ, Div Med Oncol, Dept Internal Med, Sch Med, Tokyo, Japan

[3] Japanese Red Cross Okayama Hosp, Resp Med, Okayama, Japan

[4] Yokohama Municipal Citizens Hosp, Yokohama, Kanagawa, Japan

[5] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[6] Chiba Univ, Chiba, Japan

[7] Kurume Univ, Sch Med, Kurume, Fukuoka, Japan

[8] Thorac Oncol Res Grp, Yokohama, Kanagawa, Japan

来源：

关键词：

NSCLC; performance status; nab-Paclitaxel;

D O I：

10.1016/j.jtho.2019.08.730

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-15

引用

页码：S361 / S361

页数：1